CVS Health Corp vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? CVS Health Corp trades at $94.93 (market cap $119.58B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $123.18. The key difference: CVS Health Corp pays a 2.84% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, CVS Health Corp nearer its low. Which is the better fit depends on your goals.
| CVS | QQQE | |
|---|---|---|
Market Cap | $119.58B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $110.60 | $122.72 |
52-Week Low | $65.51 | $96.06 |
Enterprise Value | $181.93B | — |
Dividend Yield | 2.84% | — |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $94.12, down 1.62% today, but maintains strong analyst support with 33 buy ratings and a $115.90 consensus price target. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $2.58 beating expectations by 38%. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, while fundamentals reveal solid revenue growth to $402.07B in 2025 despite margin compression.
CVS presents a compelling value opportunity with attractive valuation ratios (P/S: 0.29, P/B: 1.5) and strong institutional confidence. Near-term catalysts include continued Aetna recovery and healthcare services expansion, though risks include 2027 PBM pressures and margin volatility. The stock offers 23% upside to analyst targets with defensive healthcare positioning.
QQQE trades at $123.25, up 0.9% on the day, with a bullish technical signal from moving averages but a neutral oscillator reading. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk in top holdings like tech giants. Recent news highlights its appeal as a defensive play amid the Nasdaq rally, with SpaceX's imminent inclusion potentially driving inflows.
The outlook remains positive given structural diversification benefits and growth exposure, though overbought RSI levels near 79 suggest near-term caution. Risks include market volatility and tech sector sensitivity, but analyst sentiment favors QQQE over market-cap-weighted peers for balanced Nasdaq participation.
Trailing returns across standard periods
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →